We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




High HbA1c Levels Do Not Always Lead to Diabetes

By LabMedica International staff writers
Posted on 25 Jul 2019
Prediabetes is an asymptomatic condition preceding type 2 diabetes. More...
It is characterized by hyperglycemia, which is defined as a blood glucose level that is higher than normal but below the level for a clinical diagnosis of diabetes.

Glycated hemoglobin (HbA1c) values increase with age amongst diabetes‐free subjects, and low glucose level may increase mortality in old age. Questions remain on which factors are related to the reversion from prediabetes to normoglycemia, independently of mortality amongst the older population.

Scientists at the Karolinska Institute (Stockholm, Sweden) followed 2,575 men and women aged 60 and older without diabetes for up to 12 years. At the start of the study, 918 people, or 36% of the group, did have higher-than-normal blood sugar levels that were still below the threshold for diabetes.

HbA1c was collected at regular interval and until December 2010, HbA1c was assessed with Swedish Mono‐S filament High Performance Liquid Chromatography, and 1.1% was added to the individual's values to render them equal to international values in accordance with National Glycohemoglobin Standardization Program (NGSP; HbA1c in %). Since 1 January 2011, HbA1c has been assessed with the International Federation of Clinical Chemistry (IFCC) reference method. A standard equation (NGSP = [0.9148 * IFCC] + 2.152) was applied to convert IFCC HbA1c (in mmol mol−1) to NGSP value (in %), to render HbA1c results from all waves comparable.

The scientists reported that only 119 people, 13% of those who started out with elevated blood sugar, went on to develop diabetes. Another 204, or 22%, had blood sugar levels drop enough to no longer be considered prediabetic. Obese adults with prediabetes were more likely to progress to full-blown diabetes. Ying Shang, MMSc, of the Aging Research Center at the Karolinska Institute and first author of the study, said, “Progressing to diabetes is not the only destination. In fact, the chance to stay prediabetic or even revert back to (normal blood sugar) is actually pretty high (64%), without taking medication. Lifestyle changes such as weight management or blood pressure control may help stop prediabetes from progressing.” The study was published on June 4, 2019, in the Journal of Internal Medicine.

Related Links:
Karolinska Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.